A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility

Over the past year, two major policy initiatives have been introduced focusing on stimulating antibiotic development for human consumption. The European Investment Bank has announced the development of the Infectious Disease Financing Facility (IDFF) and the British government commissioned the Revie...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Globalization and health Ročník 12; číslo 1; s. 8
Hlavní autori:	Brogan, David M., Mossialos, Elias
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 22.03.2016 BioMed Central Ltd Springer Nature B.V
Predmet:	Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antimicrobial agents Capital Financing - methods Commentary Communicable Disease Control - methods Communicable diseases Communicable Diseases - drug therapy Development Economics Drug resistance Drug resistance in microorganisms Drug Resistance, Microbial - drug effects Drug therapy Epidemiology Evaluation Forecasts and trends Health Services Research Humans Incentives Infectious diseases International Cooperation Medicine Medicine & Public Health Pharmaceutical industry Public Health Public Health - methods Public health administration Quality of Life Research R&D Research & development Social Policy International Disease Financing Facility Antibiotic development Review on Antimicrobial Resistance
ISSN:	1744-8603, 1744-8603
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Over the past year, two major policy initiatives have been introduced focusing on stimulating antibiotic development for human consumption. The European Investment Bank has announced the development of the Infectious Disease Financing Facility (IDFF) and the British government commissioned the Review on Antimicrobial Resistance, led by Jim O’Neill. Each constitutes a major effort by the European community to address the evolving crisis of antimicrobial resistance. Though both have similar goals, the approaches are unique and worthy of consideration. This manuscript utilizes a previously published framework for evaluation of antibiotic incentive plans to clearly identify the strengths and weaknesses of each proposal. The merits of each proposal are evaluated in how they satisfy four key objectives: 1) Improve the overall net present value (NPV) for new antibiotic projects; 2) Enable greater participation of Small to Medium Sized Enterprises (SME); 3) Encourage participation by large pharmaceutical companies; 4) Facilitate cooperation and synergy across the antibiotic market. The IDFF seeks to make forgivable loans to corporations with promising compounds, while the O’Neill group proposes a more comprehensive framework of early stage funding, along with the creation of a stable global market. Ultimately, the proposals may prove complementary and if implemented together may form a more comprehensive plan to address an impending global crisis. Substantial progress will only be made on these efforts if action is taken at an international level, therefore we recommend consideration of these efforts at the upcoming G20 summit.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	1744-8603 1744-8603
DOI:	10.1186/s12992-016-0147-y